News

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary

Verona cues up filings for COPD drug after it aces phase 3 test

https://pharmaphorum.com/news/verona-cues-up-filings-for-copd-drug-after-it-aces-phase-3-test/

Tagrisso paired with Hutchmed drug clears lung cancer test

Phil Taylor AstraZeneca, HutchMed, Non-small cell lung cancer, Oncology, Orpathys, Tagrisso, targeted oncology 0 Comment

EGFR inhibitors like AstraZeneca’s Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of

Tagrisso paired with Hutchmed drug clears lung cancer test

https://pharmaphorum.com/news/tagrisso-paired-with-hutchmed-drug-clears-lung-cancer-test/

News/ News/ R&D

Sosei Heptares banks $30m milestone in Neurocrine Bio alliance

Phil Taylor Karuna Therapeutics, Neurocrine Biosciences, partnering, Psychiatry, schizophrenia, Sosei Heptares 0 Comment

Sosei Heptares has taken another of its partnered G protein-coupled receptor (GPCR) programmes into mid-stage clinical trials, earning

Sosei Heptares banks $30m milestone in Neurocrine Bio alliance

https://pharmaphorum.com/news/sosei-heptares-banks-30m-milestone-in-neurocrine-bio-alliance/

News/ News/ R&D

Gilead snaps up MiroBio and its checkpoint agonists for $405m

Phil Taylor AnaptysBio, Eli Lilly, Gilead Sciences, Immunology and inflammation, M&A, MiroBio 0 Comment

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a

Gilead snaps up MiroBio and its checkpoint agonists for $405m

https://pharmaphorum.com/news/gilead-snaps-up-mirobio-and-its-checkpoint-agonists-for-405m/

News/ News/ R&D

Amgen splashes out on ChemoCentryx and its blockbuster hopeful

Phil Taylor Amgen, ChemoCentryx, Immunology and inflammation, M&A, nephrology, Tavneos 0 Comment

Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in

Amgen splashes out on ChemoCentryx and its blockbuster hopeful

https://pharmaphorum.com/news/amgen-splashes-out-on-chemocentryx-and-its-blockbuster-hopeful/

News/ News/ R&D

Pfizer takes pipeline blow as it abandons cardiomyopathy drug

Phil Taylor Array Biopharma, cardiomyopathy, Pfizer, rare disease 0 Comment

Pfizer has stopped development of a drug to treat cardiomyopathy caused by a rare form of heart disease,

Pfizer takes pipeline blow as it abandons cardiomyopathy drug

https://pharmaphorum.com/news/pfizer-takes-pipeline-blow-as-it-abandons-cardiomyopathy-drug/

News/ News/ News/ Oncology/ R&D

Keytruda fluffs its lines in prostate, liver cancer trials

Phil Taylor immuno-oncology, Keytruda, Liver cancer, Merck & Co, Oncology, Prostate cancer 0 Comment

Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver

Keytruda fluffs its lines in prostate, liver cancer trials

https://pharmaphorum.com/news/keytruda-fluffs-its-lines-in-prostate-liver-cancer-trials/

News/ News/ News/ Oncology/ R&D

Roche adds to pipeline with Poseida, Kiniksa deals

Phil Taylor CAR-T therapies, Genentech, Kiniksa Pharmaceuticals, partnering, Poseida Therapeutics, prurigo nodularis, Roche 0 Comment

Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline

Roche adds to pipeline with Poseida, Kiniksa deals

https://pharmaphorum.com/news/roche-adds-to-pipeline-with-poseida-kiniksa-deals/

News/ News/ R&D

Chinese biotech Sironax raises $200m for RIPK1 pipeline

Phil Taylor China, Eli Lilly, financing, Genfleet Therapeutics, GlaxoSmithKline, Immunology and inflammation, Rigel Pharmaceuticals, RIPK1, Sanofi, Sironax 0 Comment

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire

Chinese biotech Sironax raises $200m for RIPK1 pipeline

https://pharmaphorum.com/news/chinese-biotech-sironax-raises-200m-for-ripk1-pipeline/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

News

Login